Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report issued on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

TENX has been the subject of a number of other research reports. Leerink Partners set a $20.00 price target on Tenax Therapeutics in a report on Monday, March 10th. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Stock Performance

Shares of Tenax Therapeutics stock opened at $6.43 on Friday. The firm has a 50-day simple moving average of $6.44 and a two-hundred day simple moving average of $5.31. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.89.

Institutional Investors Weigh In On Tenax Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 5,964 shares during the period. Two Sigma Investments LP purchased a new position in Tenax Therapeutics in the fourth quarter worth approximately $84,000. Millennium Management LLC acquired a new stake in Tenax Therapeutics during the fourth quarter worth $166,000. Sphera Funds Management LTD. purchased a new stake in Tenax Therapeutics in the third quarter valued at $101,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Tenax Therapeutics in the 3rd quarter valued at $173,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.